File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: When do children convert from liquid antiretroviral to solid formulations?

TitleWhen do children convert from liquid antiretroviral to solid formulations?
Authors
KeywordsAge of conversion
Antiretroviral
Formulation
Long-term treatment
Retention
Issue Date2005
PublisherSpringer Verlag Dordrecht. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0928-1231
Citation
Pharmacy World And Science, 2005, v. 27 n. 5, p. 399-402 How to Cite?
AbstractBackground: Liquid formulations are usually regarded as the gold standard in paediatric formulation; but sometimes, liquid formulations have stability and taste problems as well as being inconvenient for travelling. Therefore, for the management of long-term illness, some older children, parents and clinicians would prefer to use solid formulations. However, there is a lack of studies to investigate the age at which children are converted from liquid to solid formulations. Objectives: (1) To investigate the age range at which children convert from liquid antiretroviral drug formulations to solid formulations, the formulations are abacavir, didanosine, lamivudine, stavudine, and zidovudine. (2) To calculate how long children stay on each of five UK liquid formulations (retention time) and factors affecting the retention times of the above liquid formulations. Method: This was a retrospective medical records survey at Great Ormond Street Hospital for Children, London, United Kingdom. Patients' treatment details were entered into SPSS for Windows v. 11.0 and the retention times for the above liquid formulations were calculated i.e., from initiation of the liquid treatment to conversion to solid preparation. The retention times of different preparations were then compared using Cox regression analysis. Results: A total of 92 patients are included in the analysis. The overall average age at conversion was 7.3 years (95% CI 6.3-8.2). Patients on stavudine were more likely to switch to the corresponding solid dose form than the other four medicines (P < 0.001); more than 50% of patients on stavudine switched to solid formulation after nine months of treatment, however, less than 25% of patients on other formulations switched during the same period. Conclusion:Children taking antiretroviral liquid preparations change to solid dose forms at approximately seven years of age. However, for stavudine, children are more likely to take the solid form at an earlier age. © Springer 2005.
Persistent Identifierhttp://hdl.handle.net/10722/132883
ISSN
2012 Impact Factor: 1.265
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYeung, VWen_HK
dc.contributor.authorWong, ICKen_HK
dc.date.accessioned2011-04-04T07:57:46Z-
dc.date.available2011-04-04T07:57:46Z-
dc.date.issued2005en_HK
dc.identifier.citationPharmacy World And Science, 2005, v. 27 n. 5, p. 399-402en_HK
dc.identifier.issn0928-1231en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132883-
dc.description.abstractBackground: Liquid formulations are usually regarded as the gold standard in paediatric formulation; but sometimes, liquid formulations have stability and taste problems as well as being inconvenient for travelling. Therefore, for the management of long-term illness, some older children, parents and clinicians would prefer to use solid formulations. However, there is a lack of studies to investigate the age at which children are converted from liquid to solid formulations. Objectives: (1) To investigate the age range at which children convert from liquid antiretroviral drug formulations to solid formulations, the formulations are abacavir, didanosine, lamivudine, stavudine, and zidovudine. (2) To calculate how long children stay on each of five UK liquid formulations (retention time) and factors affecting the retention times of the above liquid formulations. Method: This was a retrospective medical records survey at Great Ormond Street Hospital for Children, London, United Kingdom. Patients' treatment details were entered into SPSS for Windows v. 11.0 and the retention times for the above liquid formulations were calculated i.e., from initiation of the liquid treatment to conversion to solid preparation. The retention times of different preparations were then compared using Cox regression analysis. Results: A total of 92 patients are included in the analysis. The overall average age at conversion was 7.3 years (95% CI 6.3-8.2). Patients on stavudine were more likely to switch to the corresponding solid dose form than the other four medicines (P < 0.001); more than 50% of patients on stavudine switched to solid formulation after nine months of treatment, however, less than 25% of patients on other formulations switched during the same period. Conclusion:Children taking antiretroviral liquid preparations change to solid dose forms at approximately seven years of age. However, for stavudine, children are more likely to take the solid form at an earlier age. © Springer 2005.en_HK
dc.languageengen_US
dc.publisherSpringer Verlag Dordrecht. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0928-1231en_HK
dc.relation.ispartofPharmacy World and Scienceen_HK
dc.subjectAge of conversionen_HK
dc.subjectAntiretroviralen_HK
dc.subjectFormulationen_HK
dc.subjectLong-term treatmenten_HK
dc.subjectRetentionen_HK
dc.titleWhen do children convert from liquid antiretroviral to solid formulations?en_HK
dc.typeArticleen_HK
dc.identifier.emailWong, ICK: wongick@hku.hken_HK
dc.identifier.authorityWong, ICK=rp01480en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/s11096-005-7911-zen_HK
dc.identifier.pmid16341747-
dc.identifier.scopuseid_2-s2.0-28844462985en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-28844462985&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume27en_HK
dc.identifier.issue5en_HK
dc.identifier.spage399en_HK
dc.identifier.epage402en_HK
dc.identifier.isiWOS:000233869000008-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridYeung, VW=9841023300en_HK
dc.identifier.scopusauthoridWong, ICK=7102513915en_HK
dc.identifier.citeulike437397-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats